UBS confirms its neutral opinion on the stock and lowers its target price to 248 Swiss francs (from 262 Swiss francs) following the announcement of Q4 2023 results. This target represents an upside potential of 6%.

' Roche's Q4 EBIT miss was followed by guidance for FY2024 below UBS and market expectations '.

' The momentum remains challenging until clear progress is made ' says UBS.

Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.